10x Genomics reported a loss for the third quarter, missing both earnings and revenue expectations. The company cited sales restructuring and cautious customer spending as factors. While the stock initially declined, it rebounded on Wednesday, likely due to the reduced revenue guidance indicating a potential bottoming out of the company’s performance. Analyst ratings remain mixed, with some maintaining their buy recommendations despite lowering price targets.
10x Genomics reported a loss for the third quarter, missing both earnings and revenue expectations. The company cited sales restructuring and cautious customer spending as factors. While the stock initially declined, it rebounded on Wednesday, likely due to the reduced revenue guidance indicating a potential bottoming out of the company’s performance. Analyst ratings remain mixed, with some maintaining their buy recommendations despite lowering price targets.
10x Genomics, a leader in single-cell and spatial biology, announced its Q3 2024 financial results, revealing a slight revenue decline attributed to sales restructuring and cautious customer spending. Despite the challenges, the company remains optimistic about future growth, driven by its new product launches and the expanding market for its innovative technologies.
10x Genomics, a leader in single-cell and spatial biology, announced its Q3 2024 financial results, revealing a slight revenue decline attributed to sales restructuring and cautious customer spending. Despite the challenges, the company remains optimistic about future growth, driven by its new product launches and the expanding market for its innovative technologies.
